The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of the PI3K inhibitor buplarlisib (B) with concurrent chemoradiotherapy (CRT) in patients with high risk locally advanced squamous cell cancer of the head and neck (LASCCHN).
 
Jochen H. Lorch
Consulting or Advisory Role - Eisai
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Millennium (Inst); Novartis (Inst)
 
Roy B. Tishler
No Relationships to Disclose
 
Nicole Grace Chau
Research Funding - GlaxoSmithKline; Merck (Inst); Pfizer (Inst)
 
Glenn J. Hanna
Research Funding - Bristol-Myers Squibb (Inst)
 
Guilherme Rabinowits
Stock and Other Ownership Interests - Regeneron; Syros Pharmaceuticals
Consulting or Advisory Role - EMD Serono; Pfizer
Research Funding - EMD Serono (Inst); Exelixis (Inst); Millennium (Inst)
 
Jonathan Daniel Schoenfeld
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Debiopharm Group; Nanobiotix; Tilos Therapeutics
Research Funding - Bristol-Myers Squibb; Merck
 
Danielle Nina Margalit
No Relationships to Disclose
 
Anne M. O'Neill
No Relationships to Disclose
 
Donald Annino
No Relationships to Disclose
 
Laura A Goguen
No Relationships to Disclose
 
Ravi Uppaluri
No Relationships to Disclose
 
Ethan James Harris
No Relationships to Disclose
 
Alec Kacew
No Relationships to Disclose
 
Julian Huang
No Relationships to Disclose
 
Laura Ma
No Relationships to Disclose
 
Patricia Mchugh
No Relationships to Disclose
 
Robert I. Haddad
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Eisai; Merck; Pfizer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Merck (Inst); VentiRx (Inst)